US
Canada
LUCIRA HEALTH ANNOUNCES NATIONAL LAUNCH OF LUCIRA CONNECT TEST-TO-TREAT SERVICE
Emeryville, Calif., (November 17, 2022) — Lucira Health, Inc. (“Lucira Health” or “Lucira”) (Nasdaq: LHDX) today announced the launch of Lucira Connect, a new virtual care program that allows Lucira test users the ability to test, learn about treatment options, access a telehealth consultation, and if appropriate, receive a prescription all from home for only the $29 price of the test, excluding prescription costs.
Lucira Connect is a user-friendly web-based platform at www.luciraconnect.com available nationwide and begins with self-administration of Lucira’s simple at-home molecular COVID-19 test. 98% accurate results are delivered in less than 30 minutes and users can capture their test results via their smartphone. If the test result is positive for COVID-19, users will have the option to access a virtual telehealth consultation to discuss their risk factors and appropriate treatment options with an independent medical professional.
Lucira is also partnering with Pfizer Inc. to increase awareness and education about the risks of COVID-19 and the availability of treatment options. Pfizer is providing educational and risk assessment resources to be available on Lucira Connect to help test users understand their risk of progression to severe COVID-19.
“Rapid care from diagnosis to treatment is essential for managing you and your family’s health and for reducing the spread of COVID-19,” said Erik Engelson, President and CEO of Lucira Health. “Since our inception, we have been driven to revolutionize the testing industry by offering accurate and accessible healthcare from the comfort and safety of your home. The Lucira Connect program is one of the fastest and simplest ways to learn if you have COVID-19, understand what you can do about it, and to access appropriate treatment if prescribed by a medical professional. Through these partnerships, we aim to help simplify the way people access reliable information about their health and navigate COVID-19 infections to improve outcomes.”
About Lucira Health
Lucira is a medical technology company focused on the development and commercialization of innovative infectious disease tests to make lab-quality diagnostics more accessible. Lucira designed its test platform to provide accurate, reliable, PCR-quality test results anywhere and at any time. Beyond its already commercialized molecular COVID-19 and COVID-19 & Flu Tests, Lucira is working on new diagnostic tests for respiratory infections and other categories including women’s health and sexually transmitted infections (STIs). For more information, visit www.lucirahealth.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “can,” “will,” “allow,” “aim” and similar expressions are intended to identify forward-looking statements. These forward-looking statements, including but not limited to, statements regarding the accuracy of our COVID-19 test, the demand and features of the Lucira Connect program and our partnership with Pfizer, are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. These risks and uncertainties are described more fully in the “Risk Factors” section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our most recent Annual Report on Form 10-K and subsequently filed reports. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and we assume no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
Media Contacts:
Mike Stommel
323-333-2901
Investor Contact
Greg Chodaczek
Investorrelations@lucirahealth.com
332-895-3230
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/0014f81a-2c4b-475e-bb90-cf78f34b2325
https://www.globenewswire.com/NewsRoom/AttachmentNg/e5aeb830-a0c7-40ef-b666-e940a7b9c170
https://www.globenewswire.com/NewsRoom/AttachmentNg/541f7521-2b4e-4c3e-91d6-c48901705b34
Lucira is the 98% accurate, lab-quality at-home test you can rely on to tell you if you have Covid. Now with Lucira Connect, get one-touch access to a FREE telehealth session to assess care and treatment options without the need of visiting a doctor’s office.
The Lucira Covid-19 Test provides 98% accurate, lab-quality results in 30 minutes or less. Now with Lucira Connect, you also get FREE telehealth with a doctor to assess your Covid care options and get prescribed treatment, all from the comfort of home.
Timing is everything when it comes to getting Covid treatment. The sooner you can get antivirals, the more effective they can be. Lucira Connect is the faster, FREE way to get the care you need: 98% accurate testing, one-touch access to FREE telehealth, and same-day prescribed medications – all from the comfort of home.
Lorem ipsum dolor sit amet consectetur adipiscing elit dolor
Lucira Health announced today both the nationwide launch of its breakthrough Lucira COVID-19 & Flu Home Test in the United States, as well as the combination test’s inclusion in the Australian Register of Therapeutic Goods (ARTG) for use by healthcare professionals in a point-of-care setting
With 99% accuracy and within 30 minutes, institutions will simultaneously and accurately test residents, health workers and visitors for COVID-19 and Flu A/B
Lucira’s COVID-19 & Flu Test performed comparably in a head-to-head comparison study with highly sensitive lab-based PCR tests
These home tests have not been FDA cleared or approved. These home tests have been authorized by FDA under Emergency Use Authorization (EUA). These home tests have been authorized only for the testing of nasal swabs for detection of nucleic acid from SARS-CoV-2 alone, or from SARS-CoV-2, influenza A, and influenza B; not for any other viruses or pathogens. These home tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of IVDs for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or revoked sooner.
Monday -Friday 7:00am-5:00pm PT
© 2023 Lucira Health, Inc. All rights reserved.